Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Íñigo Rua-Figueroa Fernández de Larrinoa, María J Cuadrado Lozano, Carlos Marras Fernández-Cid, Tatiana Cobo Ibáñez, Tarek C Salman Monte, Mercedes Freire González, Francisco J Hidalgo Bermejo, Carmen San Román Gutiérrez & Josefina Cortés-Hernández. (2022) Preventing organ damage in systemic lupus erythematosus: the impact of early biological treatment. Expert Opinion on Biological Therapy 22:7, pages 821-829.
Read now
Read now
Ying Ding, Ying Tan, Zhen Qu & Feng Yu. (2020) Renal microvascular lesions in lupus nephritis. Renal Failure 42:1, pages 19-29.
Read now
Read now
Chi Chiu Mok. (2019) The Jakinibs in systemic lupus erythematosus: progress and prospects. Expert Opinion on Investigational Drugs 28:1, pages 85-92.
Read now
Read now
Articles from other publishers (16)
Sabina Ciciriello, Geoffrey Littlejohn, Catherine O’Sullivan, Tegan Smith & Claire T. Deakin. (2023) Burden of disease and real-world treatment patterns of patients with systemic lupus erythematosus in the Australian OPAL dataset. Clinical Rheumatology 42:11, pages 2971-2980.
Crossref
Crossref
Chi Chiu Mok, Ling Yin Ho, Kar Li Chan, Sau Mei Tse & Chi Hung To. (2023) Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Associated with Disease Activity and Risk of Incident Cardiovascular Disease in Patients with Systemic Lupus Erythematosus. Inflammation 46:4, pages 1458-1470.
Crossref
Crossref
Chi Chiu Mok, Y. K. Onno Teng, Ramesh Saxena & Yoshiya Tanaka. (2023) Treatment of lupus nephritis: consensus, evidence and perspectives. Nature Reviews Rheumatology 19:4, pages 227-238.
Crossref
Crossref
Pang Chen, Yadong Zhou, Lianghua Wu, Shihan Chen & Fangduo Han. (2023) Efficacy and Safety of Biologic Agents for Lupus Nephritis. JCR: Journal of Clinical Rheumatology 29:2, pages 95-100.
Crossref
Crossref
Alvaro Gomez & Ioannis Parodis. (2022) Do biological agents improve health-related quality of life in patients with systemic lupus erythematosus? Results from a systematic search of the literature. Autoimmunity Reviews 21:11, pages 103188.
Crossref
Crossref
Chi Chiu Mok. (2020) The dawn of a new era of therapies in systemic lupus erythematosus. Rheumatology and Immunology Research 1:1, pages 31-37.
Crossref
Crossref
Kashyap K. Dubey, Indu & Manisha Sharma. (2020) Reprogramming of antibiotics to combat antimicrobial resistance. Archiv der Pharmazie 353:11.
Crossref
Crossref
Chi Chiu Mok, Ling Yin Ho, Shirley King Yee Ying, Man Chi Leung, Chi Hung To & Woon Leung Ng. (2020) Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis. Annals of the Rheumatic Diseases 79:8, pages 1070-1076.
Crossref
Crossref
Jared Klarquist, Rachel Cantrell, Maria A. Lehn, Kristin Lampe, Cassandra M. Hennies, Kasper Hoebe & Edith M. Janssen. (2020) Type I IFN Drives Experimental Systemic Lupus Erythematosus by Distinct Mechanisms in CD4 T Cells and B Cells. ImmunoHorizons 4:3, pages 140-152.
Crossref
Crossref
Catherine H. Schein. (2019) Repurposing approved drugs on the pathway to novel therapies. Medicinal Research Reviews 40:2, pages 586-605.
Crossref
Crossref
Ena Ladi, Christine Everett, Craig E. Stivala, Blake E. Daniels, Matthew R. Durk, Seth F. Harris, Malcolm P. Huestis, Hans E. Purkey, Steven T. Staben, Martin Augustin, Michael Blaesse, Stefan Steinbacher, Celine Eidenschenk, Rajita Pappu & Michael Siu. (2019) Design and Evaluation of Highly Selective Human Immunoproteasome Inhibitors Reveal a Compensatory Process That Preserves Immune Cell Viability. Journal of Medicinal Chemistry 62:15, pages 7032-7041.
Crossref
Crossref
Qingjun Pan, Xiaoqun Chen, Shuzhen Liao, Xiaocui Chen, Chunfei Zhao, Yong-zhi Xu & Hua-feng Liu. (2019) Updated advances of linking psychosocial factors and sex hormones with systemic lupus erythematosus susceptibility and development. PeerJ 7, pages e7179.
Crossref
Crossref
Thomas Dörner & Richard Furie. (2019) Novel paradigms in systemic lupus erythematosus. The Lancet 393:10188, pages 2344-2358.
Crossref
Crossref
Bimba F. Hoyer & Thomas Dörner. 2019. Dubois' Lupus Erythematosus and Related Syndromes. Dubois' Lupus Erythematosus and Related Syndromes
710
718
.
Yemil Atisha-Fregoso, Yong-Rui Zou & Betty Diamond. 2019. Dubois' Lupus Erythematosus and Related Syndromes. Dubois' Lupus Erythematosus and Related Syndromes
101
115
.
Chi Chiu Mok. (2018) Is Treat-to-target in Lupus Nephritis Realistic in Clinical Practice?. Current Rheumatology Reviews 15:1, pages 2-6.
Crossref
Crossref